Head and neck cancer is the sixth most common cancer worldwide. Patients diagnosed with this malignancy typically show a poor prognosis mainly due to late diagnosis, limited response to therapy, and high recurrence rates. A great effort in basic research has been done to overcome these limitations with the ultimate goal of improving the overall survival of patients. In this context, translational research has been instrumental to enable the transition of data from the laboratory bench as therapeutic alternatives to the patient's bedside. As an example, newly discovered pharmacological agents are already being evaluated in clinical trials for the prevention and treatment of head and neck cancer, including salivary gland malignancies. In fact, patients diagnosed with such tumors that typically had a dismal prognosis are now being benefited from novel therapies, most of them involving the utilization of targeted drugs in the context of personalized medicine.
This Special Research Topic aims to collect the most recent evidence on the development of therapeutic agents including, but not limited to, the methodology, the efficacy as well as the implementation of such interventions in a pre-clinical and clinical setting. Another major goal of this Special Issue is to encourage a systematic review of the current state-of-the-art literature in head and neck cancer translational research.
High-quality original research, reviews, and mini reviews involving potentially translational experimental and clinical research data are welcome. Areas of interest include, but are not limited to, the following topics:
- Translational methods utilizing patient-derived xenograft (PDX) and other innovative cancer models to facilitate head and neck cancer research.
- Head and neck cancer chemo-preventive regimens.
- Head and neck cancer translational diagnostic tools to improve response to therapy.
- Head and neck cancer targeted and personalized therapy.
Head and neck cancer is the sixth most common cancer worldwide. Patients diagnosed with this malignancy typically show a poor prognosis mainly due to late diagnosis, limited response to therapy, and high recurrence rates. A great effort in basic research has been done to overcome these limitations with the ultimate goal of improving the overall survival of patients. In this context, translational research has been instrumental to enable the transition of data from the laboratory bench as therapeutic alternatives to the patient's bedside. As an example, newly discovered pharmacological agents are already being evaluated in clinical trials for the prevention and treatment of head and neck cancer, including salivary gland malignancies. In fact, patients diagnosed with such tumors that typically had a dismal prognosis are now being benefited from novel therapies, most of them involving the utilization of targeted drugs in the context of personalized medicine.
This Special Research Topic aims to collect the most recent evidence on the development of therapeutic agents including, but not limited to, the methodology, the efficacy as well as the implementation of such interventions in a pre-clinical and clinical setting. Another major goal of this Special Issue is to encourage a systematic review of the current state-of-the-art literature in head and neck cancer translational research.
High-quality original research, reviews, and mini reviews involving potentially translational experimental and clinical research data are welcome. Areas of interest include, but are not limited to, the following topics:
- Translational methods utilizing patient-derived xenograft (PDX) and other innovative cancer models to facilitate head and neck cancer research.
- Head and neck cancer chemo-preventive regimens.
- Head and neck cancer translational diagnostic tools to improve response to therapy.
- Head and neck cancer targeted and personalized therapy.
